摘要
分两部分介绍了抗HIV的化学治疗药物的新进展,一是作用于现有病毒靶位的属于逆转录酶抑制剂和蛋白酶抑制剂的新化合物,另一部分是作用于病毒新靶位的化合物如HIV整合酶抑制剂、核糖核酸酶H抑制剂以及病毒进入抑制剂。主要从化学结构、对耐药性病毒的抑制作用、作用机制和临床效果等几个方面介绍了解决HIV耐药性问题的新化合物。
出处
《国外医药（抗生素分册）》
CAS
2005年第3期127-132,共6页
World Notes on Antibiotics
同被引文献20
-
1Delfraissy J, Flandre P, Delaugerre C,et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudlne in antiretroviral- naive HIV-infected patients[J]. AIDS 2008; 22(3) : 385-393.
-
2Gathe JC, Yeh RF, Mayberry C, et al. Single-agent therapy with lopiravir/ritonavir suppresses plasma HIV-1 viral replication in HIV-IMANI-2 48-week results. Eabstract WEPEB0343. [C]. 4th IAS Conference. Sydney ; Australia; 22 25 July 2007.
-
3Cameron DW, da Silva BA, Arribas JR, etal. two-year random- ized controlled clinical trial in antiretroviral-nave subjects using lopinavir/ ritonavir monotherapy after ini A tial induction treat- ment compared to an efavirenz 3-drug regimen, 96 week results, Study M03-613. In: XVIth International AIDS Conference, In ternational AIDS Society, Toronto, 2006. Abstract THLB0201. http://www, aids2006, org/PAG/Abstracts, aspx? AID= 51028 (28 January 2008, date last accessed).
-
4Pulido F, Arribas JR, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, openqabel,prooo concept pilot clinical trial (OK Study) [J]. J Acquit Immune Defic Syndr,2005, 40(3): 280-287.
-
5Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy vs lopinavir-ritonavir and two nucleosides for ma- intenance therapy of HIV [J]. AIDS, 2008, 22(2): F1-9.
-
6Nunes EP, Oliveira MS, Almeida MMTB, etal. 48-week efficacy and safety results of simplification to single agent lopinavir/ ritonavir (LPV/r) regim en in patients suppressed below 80 cop- ies/mL on HAART the KalMo study. In XVIth International AIDS Conference, International AIDS Society, Toronto, 2006.Abstract TUAB0103. http://www, iasociety, org/Default, aspx? pageId= 11 :abstractId=2191589 (28 January 2008, date last ac- cessed).
-
7McKinnon JE, Mellors JW, Swindells, et al. Simplification strat egies to reduce antiretroviral drug exposure progress and pros- pects[J]. Antivir Ther, 2009,14(1) : 1 -12.
-
8Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for ma- intenance therapy of HIV: 96-week analysis[J]. J Acquir Immune Defic Syndr, 2009,51(2) : 147-52.
-
9Delfraissy JF, Flandre P, De|augerre C, et al. Lopinavir/ritona- vir monotherapy or plus zidovudine and lamivudine in antiretrovi- ral-naive HIV-infected patients [J]. AIDS, 2008,22 (3) : 385 - 393.
-
10Ve'ronique Avettand-Fenoel, Philippe Flandre, Marie-Laure Chaix. Impact of 48 week lopinavir/ritonavir monotherapy onblood cell-associated HIV-1-DNA in the MONARK trial [J]. J Antimicrob Chemother, 2010, 65(5): 1005-1007.
-
1刘俊生.发现糖尿病药物研发的新靶位[J].生物制品快讯,2003(5):20-21.
-
2李张军,方志源,曾因明,文先杰.疼痛治疗的新靶位:T型钙通道[J].中国基层医药,2006,13(10):1744-1745.
-
3付爱玲.线粒体KATP：治疗心肌缺血的新靶位[J].第三军医大学学报,2002,25(B11):41-43.
-
4陈盈盈,张玉彬,顾觉奋.抗菌药物新靶位[J].中国医药生物技术,2012,7(4):302-305. 被引量：1
-
5唐神结,肖和平.耐药结核病的化学治疗药物及其研究进展[J].中华医学杂志,2009,89(44):3160-3162. 被引量：9
-
6王泓（编译）.实验性HIV整合酶抑制剂有助于控制病毒[J].中华医学信息导报,2006,21(18):17-17.
-
7林琳,崔秀云,王昊人,林芄.核糖核酸酶抑制因子的制备及其对BALB/c小鼠肿瘤生长的抑制作用[J].药物生物技术,1998,5(2):80-83.
-
8王波云,李立安,顾亚夫.细菌耐药性研究进展与对策[J].解放军药学学报,2001,17(5):259-261. 被引量：17
-
9买尔旦·马合木提,古丽仙·胡加,王晓雯.细菌耐药机制的研究进展[J].新疆医科大学学报,2003,26(6):609-610.
-
10日研究称儿童服用“达菲”更易导致耐药病毒出现[J].心血管病防治知识,2011(2):17-17.
